Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

PD-L1/PD-1 Pattern of Distribution within Bone Marrow Microenvironment Cells in Patients with Smoldering Myeloma and Active Multiple Myeloma

Federica Costa, Rosanna Vescovini, PhD, Laura Notarfranchi, Paola Storti, PhD, Valentina Marchica, MS, Anna Benedetta Dalla Palma, MD, Cristina Manferdini, BS, Denise Toscani, PhD, Rosalba Eufemiese, MS, Jessica Burroughs, PhD, Gina Lisignoli, PhD, Nicola Giuliani

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-139275

Published: 2020

Journal Articles

Short-Term Risk for Progression in Patients with Smoldering Multiple Myeloma: The Impact of CD56 Expression

Laura Notarfranchi, Rosanna Vescovini, PhD, Roberta Segreto, MS, Sabrina Bonomini, MS, Paola Storti, PhD, Valentina Marchica, MS, Federica Costa, Gabriella Sammarelli, PhD, Giannalisa Todaro, PhD, Maria Teresa Catarozzo, MS, Dario De Giovanni, MD, Vincenza Fabiano, MD, Anna Benedetta Dalla Palma, MD, Nicola Giuliani

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-139214

Published: 2020

Journal Articles

Glutamine Depletion By Addicted Myeloma Cells Inhibits Osteoblastic Differentiation of Bone Marrow Mesenchymal Stromal Cells Limiting Asparagine Availability: A Possible New Mechanism for Myeloma Bone Disease

Martina Chiu, PhD, Denise Toscani, PhD, Emanuela Vicario, PhD, Roberta Andreoli, PhD, Giuseppe Taurino, MS, Valentina Marchica, MS, Paola Storti, PhD, Massimiliano Bianchi, PhD, Ovidio Bussolati, MD PhD, Nicola Giuliani

Blood (2019) 134 (Supplement_1): 4339.

https://doi.org/10.1182/blood-2019-128034

Published: 2019

Journal Articles

Short-Term Risk of Progression of Patients with Asymptomatic Monoclonal Gammopathies to Active Multiple Myeloma: The Critical Impact of the Tumoral Mass

Anna Benedetta Dalla Palma, MD, Laura Notarfranchi, MD, Jessica Crosara, MD, Mario Pedrazzoni, MD, Fabrizio Accardi, MD, Valentina Marchica, MS, Denise Toscani, PhD, Emanuela Vicario, PhD, Paola Storti, PhD, Nicola Giuliani

Blood (2019) 134 (Supplement_1): 1795.

https://doi.org/10.1182/blood-2019-128252

Published: 2019

Journal Articles

Myeloma-Induced Alterations of Glutamine Metabolism Impair Bone Microenvironment Niche in Multiple Myeloma Patients

Denise Toscani, PhD, Martina Chiu, PhD, Giuseppe Taurino, MS, Emanuela Vicario, MS, Valentina Marchica, MS, Fabrizio Accardi, MD, Anna Benedetta Dalla Palma, MD, Paola Storti, PhD, Gaetano Donofrio, PhD, Franco Aversa, MD, Ovidio Bussolati, MD PhD, Nicola Giuliani, MD PhD

Blood (2018) 132 (Supplement 1): 4481.

https://doi.org/10.1182/blood-2018-99-111337

Published: 2018

Journal Articles

CD14 + CD16 + Monocyte Binding to Myeloma Cells Is Required for Daratumumab Dependent Killing in Multiple Myeloma Patients

Paola Storti, PhD, Rosanna Vescovini, PhD, Valentina Marchica, MS, Marina Bolzoni, PhD, Federica Costa, MS, Emanuela Vicario, MS, Denise Toscani, PhD, Anna Benedetta Dalla Palma, MD, Fabrizio Accardi, MD, Fabio Malavasi, MD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2018) 132 (Supplement 1): 3200.

https://doi.org/10.1182/blood-2018-99-112873

Published: 2018

Journal Articles

Relationship between Bone Marrow PD-1 and PD-L1 Expression and the Presence of Osteolytic Bone Disease in Multiple Myeloma Patients

Federica Costa, MS, Marina Bolzoni, PhD, Rosanna Vescovini, PhD, Fabrizio Accardi, MD, Anna Benedetta Dalla Palma, MD, Federica De Luca, PhD, Valentina Marchica, MS, Denise Toscani, PhD, Emanuela Vicario, MS, Paola Storti, PhD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2018) 132 (Supplement 1): 3183.

https://doi.org/10.1182/blood-2018-99-118200

Published: 2018

Journal Articles

Effect of Continuous Lenalidomide Treatment on Copy Number Alteration and Cytogenetic Abnormalities in Multiple Myeloma Cells

Paola Storti, PhD, Marina Bolzoni, PhD, Francesca Novara, PhD, Giannalisa Todaro, PhD, Valentina Marchica, Federica Costa, PhD, Tania Maldacena, PhD, Laura Notarfranchi, MD, Fabrizio Accardi, MD, Orsetta Zuffardi, PhD, Franco Aversa, MD, Nicola Giuliani, MD PhD, Gabriella Sammarelli, PhD

Blood (2017) 130 (Supplement 1): 3039.

https://doi.org/10.1182/blood.V130.Suppl_1.3039.3039

Published: 2017

Journal Articles

ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma

Matteo Marchesini, PhD, Yamini Ogoti, MS, Elena Fiorini, MS, Marianna D'anca, PhD, Paola Storti, PhD, Luigi Nezi, PhD, Mehmet K. Samur, PhD, Irene Gañán-Gómez, PhD, Mariateresa Fulciniti, PhD, Zachary S. Bohannan, MA, Karen Clise-Dwyer, PhD, Nicola Giuliani, MD PhD, Nikhil C Munshi, MD, Robert Z. Orlowski, PhD, MD, Guillermo Garcia-Manero, MD, Ronald A. DePinho, Simona Colla, PhD

Blood (2016) 128 (22): 359.

https://doi.org/10.1182/blood.V128.22.359.359

Published: 2016

Journal Articles

Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses.

Valentina Marchica, Gaetano Donofrio, PhD, Rosanna Vescovini, PhD, Giulia Tebaldi, Alfonso Rosamilia, Daniela Guasco, Paola Storti, PhD, Marina Bolzoni, PhD, Federica Costa, Chiara Schifano, MSc, Sabrina Bonomini, MSc, Fabrizio Accardi, MD, Francesco Piazza, MD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2016) 128 (22): 2093.

https://doi.org/10.1182/blood.V128.22.2093.2093

Published: 2016

Journal Articles

Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity

Denise Toscani, PhD, Marina Bolzoni, PhD, Federica Costa, Valeria Quarona, Valentina Marchica, Cristina Mancini, MD, Eugenia Martella, MD, Sabrina Bonomini, Paola Storti, PhD, Antonella Chillemi, PhD, Fabrizio Accardi, MD, Benedetta Dalla Palma, MD, Luisa Craviotto, MD, Fabio Malavasi, MD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2015) 126 (23): 2959.

https://doi.org/10.1182/blood.V126.23.2959.2959

Published: 2015

Journal Articles

Hypoxia-Inducible Factor (HIF)-1alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo

Paola Storti, PhD, Valentina Marchica, Denise Toscani, PhD, Irma Airoldi, PhD, Sophie Maiga, PhD, Marina Bolzoni, PhD, Nicoletta Campanini, Eugenia Martella, MD, Cristina Mancini, MD, Valentina Ferri, Gaetano Donofrio, PhD, Martine Amiot, PhD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2015) 126 (23): 3012.

https://doi.org/10.1182/blood.V126.23.3012.3012

Published: 2015

Journal Articles

The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4

Valentina Marchica, Fabrizio Accardi, MD, Paola Storti, PhD, Cristina Mancini, MD, Eugenia Martella, MD, Marina Bolzoni, PhD, Katia Todoerti, Chiara Schifano, Sabrina Bonomini, Benedetta Dalla Palma, MD, Magda Marcatti, MD, Maurilio Ponzoni, MD, Antonino Neri, MD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2015) 126 (23): 5315.

https://doi.org/10.1182/blood.V126.23.5315.5315

Published: 2015

Journal Articles

Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14 + Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis

Marina Bolzoni, Domenica Ronchetti, Paola Storti, PhD, Daniela Guasco, Valentina Marchica, Luca Agnelli, PhD, Benedetta Dalla Palma, MD, Fabrizio Accardi, MD, Federica Costa, Denise Toscani, Sabrina Bonomini, Benjamin Thomas, PhD, Antonino Neri, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2014) 124 (21): 28.

https://doi.org/10.1182/blood.V124.21.28.28

Published: 2014

Journal Articles

Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma

Paola Storti, PhD, Gaetano Donofrio, PhD, Valentina Marchica, Daniela Guasco, Katia Todoerti, PhD, Irma Airoldi, PhD, Judith Anderson, Marina Bolzoni, Valentina Ferri, Eugenia Martella, MD, Cristina Mancini, MD, Nicoletta Campanini, Antonino Neri, G. David Roodman, MD, PhD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2014) 124 (21): 3373.

https://doi.org/10.1182/blood.V124.21.3373.3373

Published: 2014

Journal Articles

A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome

Blood (2014) 124 (21): 523.

https://doi.org/10.1182/blood.V124.21.523.523

Published: 2014

Journal Articles

Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma

Fabrizio Accardi, MD, Martina Chiu, Marina Bolzoni, Paola Storti, PhD, Katia Todoerti, PhD, Luca Agnelli, Massimiliano Ferrari, MD, Gabriele Missale, MD, Franco Aversa, MD, Ovidio Bussolati, MD PhD, Nicola Giuliani, MD PhD

Blood (2014) 124 (21): 2067.

https://doi.org/10.1182/blood.V124.21.2067.2067

Published: 2014

Journal Articles

Relationship Between Presence Of Osteolytic Lesions, Cytogenetic Features and Bone Marrow Levels Of Cytokines and Chemokines In Multiple Myeloma Patients: Role Of Chemokine (C-C motif) Ligand 20

Nicola Giuliani, MD, PhD, Benedetta Dalla Palma, MD, Daniela Guasco, Mario Pedrazzoni, MD, PhD, Marina Bolzoni, Gabriella Sammarelli, PhD, Paola Storti, PhD, Angelica Spolzino, MD, Luisa Craviotto, MD, Massimo De Filippo, MD, Livia Ruffini, MD, Franco Aversa, MD

Blood (2013) 122 (21): 3110.

https://doi.org/10.1182/blood.V122.21.3110.3110

Published: 2013

Journal Articles

IL3 Induces Osteoclastogenesis In Vivo and Is Modulated By Bone Marrow Monocyte / Macrophage Derived Activin A

Rebecca Silbermann, MD, Marina Bolzoni, Paola Storti, PhD, Daniela Guasco, Judith Anderson, Jolene J. Windle, PhD, G. David Roodman, MD, PhD, Nicola Giuliani, MD, PhD

Blood (2013) 122 (21): 3101.

https://doi.org/10.1182/blood.V122.21.3101.3101

Published: 2013

Journal Articles

Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo .

Marina Bolzoni, Paola Storti, PhD, Gaetano Donofrio, PhD, Irma Airoldi, PhD, Daniela Guasco, Denise Toscani, Marco Peronaci, Eugenia Martella, MD, Mirca Lazzaretti, PhD, Luca Agnelli, PhD, Ken Patrene, Cristina Mancini, MD, Martine Amiot, PhD, Antonino Neri, Simona Colla, Judith Anderson, Franco Aversa, MD, G. David Roodman, MD, PhD, Nicola Giuliani

Blood (2012) 120 (21): 2947.

https://doi.org/10.1182/blood.V120.21.2947.2947

Published: 2012

NARROW

PD-L1/PD-1 Pattern of Distribution within Bone Marrow Microenvironment Cells in Patients with Smoldering Myeloma and Active Multiple Myeloma

Short-Term Risk for Progression in Patients with Smoldering Multiple Myeloma: The Impact of CD56 Expression

Glutamine Depletion By Addicted Myeloma Cells Inhibits Osteoblastic Differentiation of Bone Marrow Mesenchymal Stromal Cells Limiting Asparagine Availability: A Possible New Mechanism for Myeloma Bone Disease

Short-Term Risk of Progression of Patients with Asymptomatic Monoclonal Gammopathies to Active Multiple Myeloma: The Critical Impact of the Tumoral Mass

Myeloma-Induced Alterations of Glutamine Metabolism Impair Bone Microenvironment Niche in Multiple Myeloma Patients

CD14 + CD16 + Monocyte Binding to Myeloma Cells Is Required for Daratumumab Dependent Killing in Multiple Myeloma Patients

Relationship between Bone Marrow PD-1 and PD-L1 Expression and the Presence of Osteolytic Bone Disease in Multiple Myeloma Patients

Effect of Continuous Lenalidomide Treatment on Copy Number Alteration and Cytogenetic Abnormalities in Multiple Myeloma Cells

ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma

Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses.

Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity

Hypoxia-Inducible Factor (HIF)-1alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo

The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4

Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma

A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome

Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma

Relationship Between Presence Of Osteolytic Lesions, Cytogenetic Features and Bone Marrow Levels Of Cytokines and Chemokines In Multiple Myeloma Patients: Role Of Chemokine (C-C motif) Ligand 20

IL3 Induces Osteoclastogenesis In Vivo and Is Modulated By Bone Marrow Monocyte / Macrophage Derived Activin A

Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo .

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only